You are here: Industry Insights > clinical program

News List

Inovio Provides Update on Clinical Program Plans for 2020 prnasia
January 06, 2020
Inovio Pharmaceuticals, Inc. announced that Inovio's President & CEO, Dr. J. Joseph Kim will present a corporate update of the company's clinical program goals for 2020 at the Biotech Showcase 2020 Conference in San Francisco, CA.
Samus Therapeutics Launches PU-AD Clinical Program in Alzheimer's Disease americanpharmaceuticalreview
July 25, 2019
Samus Therapeutics announced the initiation of its clinical program for PU-AD, an oral, brain permeable inhibitor of epichaperomes in Alzheimer's Disease (AD) following clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug
Samus Therapeutics Launches PU-AD Clinical Program in Alzheimer's Disease americanpharmaceuticalreview
July 24, 2019
Samus Therapeutics announced the initiation of its clinical program for PU-AD, an oral, brain permeable inhibitor of epichaperomes in Alzheimer's Disease (AD) following clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug
Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting firstwordpharma
December 05, 2018
Celyad (Paris:CYAD) (Brussels:CYAD) (NASDAQ:CYAD) (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced updated clinical data for the CYAD-01 p